Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Blood

Volumn 112, Issue 13, 2008, Pages 4924-4934

  Johnson, David C ^a   Corthals, Sophie ^b   Ramos, Christine ^c   Hoering, Antje ^d   Cocks, Kim ^e   Dickens, Nicholas J ^a   Haessler, Jeff ^d   Goldschmidt, Harmut ^f   Child, J Anthony ^e   Bell, Sue E ^e   Jackson, Graham ^g   Baris, Dalsu ^h   Rajkumar, S Vincent ⁱ   Davies, Faith E ^a   Durie, Brian G M ^j   Crowley, John ^d   Sonneveld, Pieter ^b   Van Ness, Brian ^c   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; CYTOKINE; DRUG;

ARTICLE; BLOOD; CONTROLLED STUDY; DNA REPAIR; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TRANSPORT; ENDOTHELIUM; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROENVIRONMENT; MOLECULAR GENETICS; MOLECULAR PROBE; MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS PREVENTION; TREATMENT RESPONSE; TUMOR CELL; VENOUS THROMBOEMBOLISM; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENETICS; HEMOSTASIS; INFORMATION PROCESSING; METABOLISM; MULTIPLE MYELOMA; PHARMACOGENETICS; RETROSPECTIVE STUDY; VEIN THROMBOSIS;

CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; CYTOKINES; DATA COLLECTION; DNA REPAIR; GENE EXPRESSION PROFILING; HEMOSTASIS; HUMANS; MULTIPLE MYELOMA; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 58149380751     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-140434     Document Type: Article

References (94)

1. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later [review]. Blood. 2008;111:3968-3977.
2. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Im-munopharmacology. 1996;31:213-221.
3. Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood. 1996;88:3972-3986.
4. Lu ZY, Zhang XG, Rodriguez C, et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood. 1995;85:2521-2527.
5. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol. 2001;125:190-197.
6. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
7. Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581-1590.
8. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66:83-88.
9. Urba ska-Rys H, Wierzbowska A, Robak T. Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw. 2003;14:40-51.
10. Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007;109:3024-3030.
11. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
12. Klein B, Zhang XG, Lu ZY, Bataille R. Interleu-kin-6 in human multiple myeloma. Blood. 1995;85:863-872.
13. DmoszynskaA, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasma. 2005;52: 175-181.
14. Hideshima T, Chauhan D, Shima Y, et al. Thalido-mide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
15. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.
16. Bennett CL, Angelotta C, Yarnold PR, et al. Tha-lidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558-2560.
17. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia. 2006;20: 1331-1340.
18. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006;134:399-405.
19. Rickles FR, Shoji M, Abe K. The role of the hemo-static system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol. 2001;73:145-150.
20. Zonder JA. Thrombotic complications of myeloma therapy. HematologyAm Soc Hematol Educ Program. 2006:348-355.
21. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexa-methasone: benefit of aspirin prophylaxis [letter]. Blood. 2006;108:403.
22. Jin SH, Kim TI, Yang KM, Kim WH. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol. 2007;558:14-20.
23. Zhang M, Abe Y, Matsushima T, Nishimura J, Nawata H, Muta K. Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk Lymphoma. 2005;46:425-433.
24. Payvandi F, Wu L, Haley M, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004;230:81-88.
25. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res. 2001;7: 3349-3355.
26. Molostvov G, MorrisA, Rose P, Basu S, Muller G. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothe-lial cell co-cultures. Br J Haematol. 2004;124:366-375.
27. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005;23:5334-5346.
28. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005;106:125-134.
29. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM.Ahigh rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629-1636.
30. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003;21:2299-2304.
31. Rabbani G, Benzil D, Wallam MN, et al. Combination therapy with thalidomide, temozolomide and tamoxifen improves quality of life in patients with malignant astrocytomas. Anticancer Res. 2007;27:2729-2736.
32. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG. Phase II study of te-mozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006;107:1883-1890.
33. Anscher MS, Garst J, Marks LB, et al. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2006;66: 477-482.
34. Dimopoulos MA, Hamilos G, ZomasA, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112-117.
35. Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol. 2002;81:357-361.
36. Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-tha-lidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22:1419-1427.
37. PalumboA, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767-2772.
38. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophospha-mide, velcade and dexamethasone induces high response rates with comparable toxicity to vel-cade alone and velcade plus dexamethasone. Haematologica. 2007;92:1149-1150.
39. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110:1042-1049.
40. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubi-cin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-762.
41. PalumboA, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-as-sociated thrombosis in myeloma. Leukemia. 2007;22:414-423.
42. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc. 2005;80:1549-1551.
43. Faham M, Zheng J, Moorhead M, et al. Multiplexed variation scanning for 1,000 amplicons in hundreds of patients using mismatch repair detection (MRD) on tag arrays. Proc Natl Acad Sci U SA. 2005;102:14717-14722.
44. Hardenbol P, Yu F, Belmont J, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res. 2005;15:269-275.
45. Moorhead M, Hardenbol P, Siddiqui F, et al. Optimal genotype determination in highly multiplexed SNP data. Eur J Hum Genet. 2006;14:207-215.
46. Arakawa K, Kono N, Yamada Y, Mori H, Tomita M. KEGG-based pathway visualization tool for complex omics data. In Silico Biol. 2005;5:419-423.
47. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004;32:D277-280.
48. Nikitin A, Egorov S, Daraselia N, Mazo I. Pathway studio - the analysis and navigation of molecular networks. Bioinformatics. 2003;19:2155-2157.
49. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet. 2004;36:431-432.
50. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006;34:D617-621.
51. Zhao T, Chang LW, McLeod HL, Stormo GD. PromoLign: a database for upstream region analysis and SNPs. Hum Mutat. 2004;23:534-539.
52. Kang HJ, Choi KO, Kim BD, Kim S, Kim YJ. FESD: a Functional Element SNPs Database in human. Nucleic Acids Res. 2005;33:D518-D522.
53. Miller RD, Phillips MS, Jo I, et al. High-density single-nucleotide polymorphism maps of the human genome. Genomics. 2005;86:117-126.
54. Johnson D. Online Supplementary data: BOAC thalidomide related thrombois study. Available at: http://www.icr.ac.uk/research/research-sections/haemato- oncology/haemato-oncology-teams/molecular-haematology-team/raw data for-publications. 2008. Accessed November 2008.
55. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet. 2007;81:559-575.
56. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
57. Garcia-Granero M. Available at: www.spsstools.net/Syntax/MetaAnalysis. Accessed November 2008.
58. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30:3894-3900.
59. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-874.
60. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4: P3.
61. Therneau T, Atkinson E. An introduction to recursive partitioning using the rpart routines. Technical report 61, Mayo Clinic 1997: http://mayore-search. mayo.edu/mayo/research/biostat/techreports.cfm. Accessed November 2008.
62. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
63. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904-909.
64. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study [abstract]. Blood. 2007;110:3593a. Abstract no. 3593.
65. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma. 2007;7:462-466.
66. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007;92:279-280.
67. van Marion AM, Auwerda JJ, Minnema MC, et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost. 2005;94: 1341-1343.
68. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost. 2005;94:797-801.
69. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 2003;1:445-449.
70. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999;5: 582-585.
71. Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res. 2003;9:4465-4474.
72. Fischer JW. Dexamethasone: effects on neointimal hyperplasia and vessel integrity. Cardiovasc Res. 2005;68:350-352.
73. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99: 4525-4530.
74. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol. 2001;115:382-391.
75. Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004;2:327-334.
76. Ohtani T, Nakamura T, Toda K, Furukawa F. Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett. 2006;580:1597-1600.
77. Vasvari G, Dyckhoff G, Herold-Mende C. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology - a rebuttal. J Thromb Haemost. 2005;3:816-817.
78. Zangari M, Barlogie B, Lee C-K, et al. Protective effect of VELCADE(R) on thalidomide-associated deep vein thrombosis (DVT) [abstract]. Blood. 2004;104:4914a. Abstract no. 4914.
79. Sohn RH, Deming CB, Johns DC, et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005;105:3910-3917.
80. Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83:588-591.
81. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80:1568-1574.
82. Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol. 2006;132:155-161.
83. Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest. 2007;131:275-277.
84. Hussein MA. Lenalidomide: patient management strategies. Semin Hematol. 2005;42:S22-25.
85. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost. 2006;95:924-930.
86. PalumboA, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost. 2006;4:1842-1845.
87. Rice L, Baker KR. Current management of the myeloproliferative disorders: a case-based review. Arch Pathol Lab Med. 2006;130:1151-1156.
88. Scarpace SL, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005;46:239-242.
89. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2003:200-224.
90. Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood. 1999;93:3831-3838.
91. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4:45-61.
92. US Food and Drug Administration. Thalidomide package insert. 2006. Available at: http://www.fda.gov/cder/foi/label/2006/021430s000,020785s031lbl. pdf. Accessed November 2008.
93. US Food and Drug Administration. Lenalidomide package insert. 2006. Available at: http://www.fda.gov/cder/foi/label/2006/021880s001.pdf. Accessed November 2008.
94. European Medicines Agency. Questions and answers on the positive opinion for Thalidomide Pharmion. 2008. Available at: http://www.emea.europa.eu/pdfs/ human/opinion/Q&A Thalidomide 54352407en.pdf. Accessed January 2008.